Platelet-derived growth factor stimulates Src-dependent mRNA stabilization of specific early genes in fibroblasts. by Bromann, Paul Andrew et al.
Platelet-derived Growth Factor Stimulates Src-dependent mRNA
Stabilization of Specific Early Genes in Fibroblasts*
Received for publication, December 8, 2004, and in revised form, December 21, 2004
Published, JBC Papers in Press, January 5, 2005, DOI 10.1074/jbc.M413806200
Paul A. Bromann‡, Hasan Korkaya‡, Craig P. Webb§, Jeremy Miller§, Tammy L. Calvin‡,
and Sara A. Courtneidge‡¶
From the ‡Laboratory of Signal Regulation and Cancer, and §Laboratory of Tumor Metastasis and Angiogenesis,
Van Andel Research Institute, Grand Rapids, Michigan 49503
The Src family of protein-tyrosine kinases (SFKs) par-
ticipates in a variety of signal transduction pathways,
including promotion of cell growth, prevention of apo-
ptosis, and regulation of cell interactions and motility.
In particular, SFKs are required for the mitogenic re-
sponse to platelet-derived growth factor (PDGF). How-
ever, it is not clear whether there is a discrete SFK-
specific pathway leading to enhanced gene expression
or whether SFKs act to generally enhance PDGF-stimu-
lated gene expression. To examine this, we treated quies-
cent NIH3T3 cells with PDGF in the presence or absence
of smallmolecule inhibitors of SFKs, phosphatidylinositol
3-kinase (PI3K), and MEK1/2. Global patterns of gene
expression were analyzed by using Affymetrix Gene-
Chip arrays, and data were validated by using reverse
transcription-PCR and ribonuclease protection assay.
We identified a discrete set of immediate early genes
induced by PDGF and inhibited in the presence of the
SFK-selective inhibitor SU6656. A subset of these SFK-
dependent genes was induced by PDGF even in the pres-
ence of theMEK1/2 inhibitor U0126 or the PI3K inhibitor
LY294002. By using ribonuclease protection assays and
nuclear run-off assays, we further determined that
PDGF did not stimulate the rate of transcription of
these SFK-dependent immediate early genes but rather
promoted mRNA stabilization. Our data suggest that
PDGF regulates gene expression through an SFK-spe-
cific pathway that is distinct from the Ras-MAPK and
PI3K pathways, and that SFKs signal gene expression by
enhancing mRNA stability.
The protein-tyrosine kinase Src was first described more
than 20 years ago. It is the prototype for a group of nonreceptor
tyrosine kinases, the Src family. Some members of this family
are restricted in their expression to hematopoietic cells,
whereas others (Src, Fyn, and Yes) are more ubiquitously ex-
pressed. SFKs1 help to transduce signals from a variety of cell
surface receptors during proliferative and immune responses.
They are also frequently activated as cells enter mitosis, rear-
range their cytoskeleton, or becomemotile (1–3). Thus, they are
involved in a diverse array of physiological processes.
Much of the understanding of SFK function comes from
analyses of fibroblasts in culture. These studies established
that SFKs participate in the mitogenic response elicited by
several peptide growth factors, including epidermal growth
factor (EGF) and PDGF (4). SFKs become activated when fi-
broblasts are stimulated with PDGF, whose receptor is itself a
tyrosine kinase (5), and associate with the PDGF receptor
(PDGF-R) (6, 7). SFKs are required for PDGF to stimulate
mitogenesis in NIH3T3 cells (8, 9). Our laboratory has recently
focused on the growth factor-stimulated production of Myc, a
transcription factor required for efficient cell cycle transit. Pre-
vious work demonstrated that the block to PDGF-stimulated
DNA synthesis caused by dominant negative SFKs could be
overcome by expression of Myc (10). Another transcription fac-
tor, Fos, was unable to rescue this block. Furthermore, Myc
could not overcome the block caused by dominant negative Ras.
Together, these data suggested that PDGF stimulation results
in the initiation of a discrete SFK signal transduction pathway,
distinct from the classical Ras-MAPK pathway, which culmi-
nates in Myc production. The subsequent characterization and
use of SU6656, an SFK inhibitor, confirmed that myc mRNA
was in large part under SFK control (9).
These studies have suggested that different PDGF effectors
might each control a discrete subset of the response of the cell
to PDGF. However, one study reported that activation of
PDGF-R led to enhanced expression of a set of immediate early
genes, and that PDGF-R mutants lacking binding sites for
individual signaling effectors (including Ras-GAP or PI3K)
failed to block expression of any of these genes (11). These data
suggested a lack of specificity in PDGF-R signaling. We decided
to address this issue by using a different approach: analyzing
global patterns of gene expression in quiescent fibroblasts stim-
ulated with PDGF in the presence or absence of various small
molecule inhibitors. These studies are reported here.
EXPERIMENTAL PROCEDURES
Cell Line and Reagents—NIH3T3 fibroblast cells were maintained in
Dulbecco’s modified Eagle’s medium with 2 mM L-glutamine, 1.5 mg/ml
glucose, 100 units/ml penicillin, 100 g/ml streptomycin, and 10% heat-
inactivated fetal bovine serum. Recombinant human PDGF-BB was
purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). SU6656
was obtained from SUGEN, Inc. (South San Francisco, CA), and U0126,
PD98059, and LY294002 were purchased from EMD Biosciences, Inc.
(La Jolla, CA). Radionuclides were purchased from Amersham Bio-
sciences (Piscataway, NJ), and all other molecular biology reagents
were purchased from Invitrogen (Carlsbad, CA). Murine Genome
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U74v2 set and Mouse Expression set 430 GeneChip arrays were pur-
chased from Affymetrix (Santa Clara, CA).
PDGF Stimulation and RNA Isolation—NIH3T3 cells were seeded at
7  105 cells/10-cm plate and grown at 37 °C in 5% CO2, 95% O2 for
24 h. Cells were then quiesced for 40 h in starvation medium (Dulbec-
co’s modified Eagle’s medium with 2 mM L-glutamine, 1.5 mg/ml glu-
cose, 100 units/ml penicillin, 100 g/ml streptomycin, 0.5% fetal bovine
serum, and 1 insulin/transferrin/selenium (Invitrogen)). After 40 h,
quiescent cells were placed in fresh starvation medium for an additional
30 min. Cells were then incubated with SU6656 (2 M), U0126 (10 M),
LY294002 (7.5 M), PD98059 (50 M), or Me2SO vehicle for 1 h. Then,
in the presence of inhibitors or vehicle, cells were stimulated for 1 h
with 25 ng/ml PDGF-BB. Total RNA was isolated using either Trizol
reagent (Invitrogen) or RNeasy mini kits (Qiagen, Valencia, CA) accord-
ing to the manufacturers’ instructions. The quality of the total RNA was
analyzed by measuring the A260/A280 ratio as well as the intensity of
18 S and 28 S rRNA on a 1% agarose gel.
Affymetrix GeneChip Analysis—The Affymetrix protocol followed
was essentially as described previously (12). Briefly, 100 pmol of a
T7-(dT)24 primer was added to 10 g of total RNA. The primer and RNA
were denatured at 70 °C for 10 min and placed on ice, and cDNA was
then synthesized by using SuperScript II RT (Invitrogen) according to
the manufacturer’s instructions. Reactions were terminated by addition
of EDTA to a final concentration of 30 mM, and samples were placed on
ice. An equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) was
added to each cDNA sample, transferred to Phase Lock gels (Eppendorf
Scientific, Westbury, NY), and centrifuged at 16,000  g for 2 min. The
aqueous upper layer was precipitated with 2.5 M ammonium acetate
and 2.5 final volume 100% ethanol. Samples were centrifuged, and
resulting pellets were washed extensively with 80% ethanol and resus-
pended in 12 l of diethyl pyrocarbonate-treated water.
The in vitro transcription labeling reactions were done using the
ENZO BioArray kit (Affymetrix) to synthesize amplified biotin-labeled
cRNA targets. The labeled cRNA was cleaned using RNeasy mini kits,
and 15 g was hybridized to Murine Genome U74Av2 or Mouse Ex-
pression 430 GeneChip arrays at the Genomics Technology Support
Facility at Michigan State University (East Lansing, MI) on a Gene-
Chip Scanner 3000 (Affymetrix). Probe intensity values were extracted
from the array image using GCOS software (Affymetrix). All of the
Affymetrix GeneChip array expression data have been deposited in the
NCBI gene expression and hybridization array data repository (acces-
sion number GSE2196).
Data Analysis—Affymetrix gene expression data were normalized to
an average intensity of 500 across each array, and the normalized CHP
files were entered into xenobase, a relational database with associated
analysis software (www.vai.org/vari/xenobase/default.asp). Data from
corresponding quiescent NIH3T3 samples were selected as reference to
allow calculation of treated/quiescent gene expression ratios. Gene ex-
pression ratios were log2-transformed prior to analysis so that relative
increases and decreases in gene expression were represented on a linear
scale. For genes called absent in test and reference samples, no fold
change in gene expression was calculated. For hierarchical clustering of
gene expression profiles, log2-transformed gene expression ratios were
loaded into and viewed with xenobase, and average linkage clustering
was carried out using correlation coefficients as described (13).
Semi-quantitative RT-PCR—Unique oligonucleotide primer pairs
were designed using Unigene sequence data from the NCBI database,
and oligonucleotides were obtained from IDT DNA Technologies
(Coralville, IA). Five g of RNeasy mini kit-purified total RNA was
reverse-transcribed with SuperScript II RT using oligo(dT) primers
(Invitrogen) according to the manufacturer’s instructions. Two l of
cDNA per reaction were amplified by PCR using gene-specific primers
as follows: 94 °C (2 min); 19–24 cycles of 94 °C (1 min), 55 °C (30 s), and
72 °C (1 min). PCRs were performed in duplicate or triplicate, and
products were visualized by using 2% agarose gel electrophoresis.
Amplification of -actin was used as an internal control.
Ribonuclease Protection Assay (RPA)—Quiescent NIH3T3 cells were
stimulated with 25 ng/ml PDGF in the presence of small molecule
inhibitors. Total RNA was isolated using the RNeasy mini kit (Qiagen).
For each reaction, 25 g of total RNA was mixed with 32P-labeled
riboprobes, which were transcribed from restriction-digested plasmid
DNA using the MAXIScript T7 kit from Ambion, Inc. (Austin, TX).
RPAs were performed using the RPA III kit from Ambion according to
the manufacturer’s instructions. Protected fragments were resolved by
PAGE using Criterion 5% TBE urea precast gels (Bio-Rad). After
PAGE, gels were transferred to filter paper, vacuum-dried, and exposed
to x-ray film for 1–6 h. Films were processed in a Kodak film developer
and scanned into Adobe Photoshop 7.0 for digital imaging.
Nuclear Run-off Assay—Quiescent NIH3T3 cells were stimulated
with 25 ng/ml PDGF for 0–60 min. Cells were washed twice in phos-
phate-buffered saline, scraped into ice-cold phosphate-buffered saline,
and centrifuged at 1000 rpm at 4 °C. The cell pellets were then resus-
pended in 500 l of ice-cold RSB buffer (10 mM Tris, pH 7.5, 10 mM
NaCl, 5 mM MgCl2, 1 mM dithiothreitol, and 1% Nonidet P-40). After 5
min of incubation on ice, the cells were disrupted by Dounce homoge-
FIG. 1. Reproducibility of Affymetrix GeneChip gene expres-
sion data. Quiescent NIH3T3 cells were treated for 1 h with 25 ng/ml
PDGF or vehicle in two separate identical experiments. Global patterns
of gene expression were identified using Affymetrix Murine Genome
U74Av2 GeneChip arrays, and gene expression ratios were log2-trans-
formed prior to analysis so that relative increases and decreases in gene
expression are represented on a linear scale. A, the log2-transformed
gene expression ratios from experiment 1 (sample/quiescent fibroblast)
were plotted against the log2-transformed gene expression ratios from
experiment 2 with a correlation coefficient of 0.87. B, the same analysis
was done for probe IDs that changed expression levels at least 2-fold in
response to PDGF between experiment 1 and 2 with a correlation
coefficient of 0.89.
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nization, and nuclei were isolated by centrifugation for 5 min at 2000
rpm at 4 °C. The nuclei were resuspended in 2 ml of ice-cold reaction
buffer (20 mM Tris, pH 7.5, 10 mM MgCl2, 140 mM KCl, 1 mM dithio-
threitol, and 20% glycerol) and pelleted by centrifugation for 5 min at
2000 rpm at 4 °C. The nuclei were then resuspended in 200 l of ice-cold
reaction buffer containing 5 mM each of ATP, CTP, GTP, and 25 Ci of
[-32P]UTP. Following 10 min of incubation at 37 °C, the nascent RNA
was extracted using Trizol and hybridized to specific DNA probes blot-
ted on Hybond-N membrane (Amersham Biosciences).
To prepare DNA probes, 400–600-bp DNA fragments from mouse
mcp-1, mcp-3, myc, adrenomedullin, fos, and -actin were amplified by
PCR using gene-specific primer pairs. Ten g of PCR product were dena-
tured by incubating in 100 mM NaOH at 100 °C for 10 min. Denatured
DNA samples and nonspecific probes were applied to nitrocellulose mem-
brane using Bio-Dot apparatus (Bio-Rad). The membrane was then air-
dried and UV cross-linked (1200 J) using a Stratalinker (Stratagene).
Immunoblotting—To detect ERK1/2 and phospho-ERK1/2, NIH3T3
cells were treated as described above and suspended in lysis buffer (20
mM Tris, pH 7.6, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 10 mM
NaF, 0.1 mM Na3VO4, 10 mM Na4P2O7, 10 mM EDTA, and protease
inhibitors). Protein bands were resolved by SDS-PAGE and transferred
to Hybond-ECL nitrocellulose membranes (Amersham Biosciences).
Membranes were blocked in TBST (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, and 0.1% Tween 20) containing 5% milk and incubated overnight
at 4 °C with anti-phospho-ERK1/2 mouse monoclonal antibody (E-4),
stripped, and reprobed using anti-ERK1/2 rabbit polyclonal antibody
(C-16, Santa Cruz Biotechnology, Santa Cruz, CA). Bound antibodies
were detected using horseradish peroxidase-linked secondary antibod-
ies (Sigma) and detected using SuperSignal West Pico chemilumines-
cent substrate (Pierce).
RESULTS
Patterns of Gene Expression in NIH3T3 Fibroblasts Are Ex-
perimentally Reproducible—To identify global patterns of
PDGF-induced immediate early gene expression in NIH3T3
cells, quiescent cells were treated for 1 h with 25 ng/ml
PDGF-BB or with vehicle. Two separate but identical experi-
ments were performed, and the total RNA from each was hy-
bridized to Affymetrix Murine Genome (MG) U74Av2 Gene-
Chip arrays as described under “Experimental Procedures.”
Because only low passage (less than 10 passages) NIH3T3 cells
were used in these studies, and because identical conditions
were used in each experiment, a high degree of data reproduc-
ibility between experiments was expected.
To eliminate low intensity noise, we analyzed gene expres-
sion data from both experiments using the following filters:
gene expression values were present in all samples, and sample
intensity values were greater than 150 units and differed by
more than 350 intensity units from quiescent NIH3T3 refer-
ence. For experiment 1, this filtering resulted in the identifi-
cation of 538 sample probe IDs that differed from the reference.
FIG. 2. Unsupervised hierarchical clustering of Affymetrix GeneChip gene expression data. Quiescent NIH3T3 cells were treated for
1 h with 25 ng/ml PDGF or vehicle in the presence of 2 M SU6656, 10 M U0126, 7.5 M LY294002, or vehicle. Global patterns of gene expression
were identified using Affymetrix Murine Genome U74Av2 GeneChip arrays, and gene expression ratios were log2-transformed prior to analysis so
that relative increases and decreases in gene expression are represented on a linear scale. These data were subjected to unsupervised hierarchical
clustering so that changes in gene expression across samples could be readily observed. Red and green boxes indicate relative high and low
expression, respectively, for the given probe ID.
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The log2-transformed gene expression ratios from experiment 1
were plotted against the log2-transformed gene expression ra-
tios from experiment 2. The resulting correlation coefficient of
0.87 demonstrated a high level of experimental reproducibility
between experiments (Fig. 1A). This set of probe IDs was fur-
ther filtered to include only probe IDs that changed expression
levels at least 2-fold in response to PDGF treatment. Again, the
log2-transformed gene expression ratios from experiment 1
were plotted against the log2-transformed gene expression ra-
tios from experiment 2. In this case, the correlation coefficient
of 0.89 further demonstrated a low level of variability in gene
expression data between experiments (Fig. 1B).
PDGF Drives Pathway-specific Gene Expression—To deter-
mine the contribution of various signaling pathways to PDGF-
induced immediate early gene expression, we analyzed global
patterns of PDGF-induced gene expression in the presence of
various small molecule inhibitors. Because we were most in-
terested in the contribution of SFKs in PDGF-induced gene
expression, we used the drug SU6656 to block SFK activity (9).
To isolate the contribution of SFKs specifically, PDGF-induced
gene expression was also analyzed in the presence of the
MEK1/2 inhibitors U0126 or PD98059, or in the presence of the
PI3K inhibitor LY294002. The concentrations of inhibitors
were selected based on the minimum concentrations of each
drug required to completely block PDGF-induced bromode-
oxyuridine incorporation in NIH3T3 cells (data not shown).
To demonstrate that inhibitor treatment alone has little
effect on overall gene expression levels, quiescent NIH3T3 cells
were treated for 1 h with 25 ng/ml PDGF or vehicle in the
presence of 2 M SU6656, 10 M U0126, 7.5 M LY294002, or
vehicle. Total RNA was hybridized to Affymetrix Mouse Ex-
pression (MOE) 430A GeneChip arrays as described under
“Experimental Procedures.” We analyzed gene expression data
by using the following filters: gene expression values were
present in all samples; sample intensity values were greater
than 50 units and differed by more than 100 intensity units
from reference values, and sample values varied at least 3-fold
with respect to quiescent NIH3T3 reference. This filtering re-
sulted in the inclusion of 29 different probe IDs. Some genes
were represented by multiple probe IDs (e.g. Tis 11b, Krupple-
like factor 4, etc.), which provides additional confirmation of
their expression patterns. These 29 probe IDs were subjected to
unsupervised hierarchical clustering so that changes in gene
expression across samples could be readily observed. The clus-
TABLE I
The expression of a subset of PDGF-inducible genes is inhibited by the SFK-specific inhibitor SU6656
Quiescent NIH3T3 cells were treated for 1 h with 25 ng/ml PDGF or vehicle in the presence of 2 M SU6656 or vehicle. Global patterns of gene
expression were identified using Affymetrix Murine Genome U74Av2 GeneChip arrays. Gene expression data were normalized to an average
intensity of 500 across each array, and the normalized CHP files were entered into xenobase, a relational database with associated analysis
software. Gene expression ratios were log2-transformed prior to analysis so that relative increases and decreases in gene expression are
represented on a linear scale. Gene expression data were analyzed using the following filters: expression values were present in all samples; values
differed by more than 100 intensity units from reference; values were equal to or greater than 50 units, and values were increased at least 2-fold
in response to PDGF. This filtering resulted in the inclusion of 127 probe IDs that were induced at least 2-fold by PDGF, and of these 36 were
induced less than 1.5-fold in response to PDGF plus 2 M SU6656. The list of these SU6656-responsive probe IDs is shown, as is the percentage
of SU6656-mediated inhibition.
Unigene Gene encodes
Log2 gene expression ratio relative to
quiescent fibroblasts Percent
inhibition
PDGF PDGF  SU6656
Mm.4679 Glial cell line-derived neurotrophic factor 140.0 21.8 84.4
Mm.289824 Interleukin 1 receptor-like 1 32.7 5.2 84.3
M19681 MCP-1 5.1 2.0 61.4
Mm.328358 cDNA clone UI-M-BH1-alc-a-02-0-UI 5 4.3 1.9 56.5
U20735 JunB 3.3 1.5 53.9
Mm.259672 Adult male aorta and vein cDNA, RIKEN full-length enriched library,
clone: A530041M22
3.0 1.4 52.8
L00039 Myc 14.3 6.8 52.3
Mm.290207 E26 avian leukemia oncogene 2, 3-domain 3.7 1.8 51.9
Mm.1408 Adrenomedullin 21.8 10.6 51.6
Mm.86541 CCR-4 16.1 7.8 51.2
D16497 Natriuretic peptide precursor type B 14.0 7.2 48.9
Mm.795 Colony-stimulating factor 1 (macrophage) 2.5 1.3 48.4
Mm.3468 Suppressor of cytokine signaling 3 3.0 1.6 47.8
U89411 Nuclear factor, interleukin 3, regulated 17.5 9.3 47.0
Mm.24402 Glutamine fructose-6-phosphate transaminase 2 23.7 12.7 46.6
Mm.18571 Tis 11b 5.1 2.8 45.0
U83148 Nuclear factor, interleukin 3, regulated 2.0 1.1 44.3
Mm.8042 Inhibin -A 4.0 2.3 42.4
Mm.3117 Pleckstrin homology-like domain, family A, member 1 4.7 2.8 41.7
Mm.282184 Vascular endothelial growth factor A 5.4 3.1 41.6
Mm.25613 Immediate early response 3 3.3 2.0 40.6
U86783 Nuclear receptor subfamily 4, group A, member 2 46.5 27.9 40.1
Mm.280895 Uridine monophosphate kinase 2.3 1.4 39.7
Mm.26147 11 days embryo head cDNA, RIKEN full-length Enriched library,
clone: 6230421P05 product: unknown EST, full insert sequence
2.6 1.6 37.5
K02236 Metallothionein 2 39.9 25.2 36.7
U20735 JunB 3.4 2.2 36.2
AV374868 Suppressor of cytokine signaling 3 2.1 1.3 36.1
M28845 Egr-1 2.5 1.6 35.8
Mm.292547 Prostaglandin-endoperoxide synthase 2 4.0 2.6 35.3
Mm.249333 RIKEN cDNA 1300002F13 gene 4.7 3.1 34.8
Mm.110220 DNA-damage inducible transcript 3 9.5 6.2 34.8
U86783 Nuclear receptor subfamily 4, group A, member 2 2.3 1.5 34.6
Mm.2706 Activating transcription factor 3 2.1 1.4 34.2
Mm.289824 Interleukin 1 receptor-like 1 11.6 7.7 34.0
X70058 MCP-3 2.5 1.6 33.7
V00835 Metallothionein 1 3.0 2.0 33.6
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ter diagram of these data, which were not mean-centered,
indicates relative high and low expression for the given probe
ID as shown in Fig. 2 by red and green boxes, respectively.
These data demonstrate that each inhibitor alone has little
effect on basal levels of gene expression and that PDGF treat-
ment induces the expression of a set of genes, which are differ-
entially affected by inhibitors. Note that whereas LY294002
alone appears to significantly alter expression of a few probe
IDs in clustering raw data, in fact when clustering mean-
centered data, these differences are less significant.
SFK-dependent Genes—To identify a set of PDGF-induced
immediate early genes that required SFK activity for expres-
sion, quiescent NIH3T3 cells were treated for 1 h with 25 ng/ml
PDGF or vehicle in the presence of 2 M SU6656 or vehicle.
Global patterns of gene expression were analyzed using Af-
fymetrix MG U74Av2 GeneChip arrays using the following
filters: values were present in all samples; sample intensity
values were equal to or greater than 50 units and differed by
more than 100 units from reference, and sample values were
increased at least 2-fold in response to PDGF. This filtering
resulted in the inclusion of 127 probe IDs that were induced at
least 2-fold by PDGF, and of these 36 were induced less than
1.5-fold in response to PDGF plus 2 M SU6656 (Table I).
We performed semi-quantitative RT-PCR as well as RPA
analysis to validate these gene expression data. By using equiv-
alent amounts of cDNA for each reaction, gene-specific primer
pairs were used to amplify small segments of the genes of
interest by PCR as described under “Experimental Proce-
dures.” Six genes were selected for RT-PCR analysis because
the array analysis suggested their expression was induced by
PDGF and inhibited by SU6656 (Table I). Reactions were per-
formed in triplicate, and -actin was used as a control for
relative amounts of template. These data demonstrate that
FIG. 3.RT-PCR and RPA analysis of PDGF-inducible genes. Qui-
escent NIH3T3 cells were treated for 1 h with 25 ng/ml PDGF or vehicle
in the presence of 2 M SU6656 or vehicle.A, by using equivalent amounts
of cDNA for each reaction, gene-specific primer pairs were used to amplify
small segments of genes by PCR. Reactions were performed in triplicate,
and -actin was used as a control for relative amounts of template cDNA.
B, ribonuclease protection assays were performed using gene-specific
probes. Reactions were performed in duplicate, and -actin was used as a
control for relative amounts of total RNA.
TABLE II
The expression of discrete sets of PDGF-responsive genes is specifically inhibited by the SFK inhibitor SU6656,
by the MEK inhibitor U0126, and by the PI3K inhibitor LY294002
Quiescent NIH3T3 cells were treated for 1 h with 25 ng/ml PDGF or vehicle in the presence of 2 M SU6656, 10 M U0126, 7.5 M LY294002,
or vehicle. Global patterns of gene expression were identified using Affymetrix MOE 430A GeneChip arrays (for details see Table I). Gene
expression data were analyzed using the following filters: values were present in all samples; values differed by more than 100 intensity units from
reference; values were increased at least 2-fold in response to PDGF, and values were decreased at least 50% in response to only one of three
inhibitors. This filtering resulted in the inclusion of 174 probe IDs that were induced at least 2-fold by PDGF, and of these 6 were specifically
inhibited at least 50% by 2 M SU6656, 11 were specifically inhibited at least 50% by 10 M U0126, and 2 were specifically inhibited at least 50%
by 7.5 M LY294002. The list of these probe IDs is shown.
Unigene Gene encodes
Log2 gene expression ratio relative to quiescent fibroblasts
PDGF PDGF  SU6656 PDGF  U0126 PDGF  LY294002
SFK-dependent
Mm.290320 MCP-1 28.4 8.9 21.1 40.0
Mm.246513 Fos 12.3 4.4 17.0 13.1
Mm.86541 CCR-4 25.8 10.2 18.3 22.0
Mm.1408 Adrenomedullin 2.7 1.2 3.2 3.8
Mm.795 Colony-stimulating factor 1
(macrophage)
3.4 1.6 2.2 3.1
Mm.259672 Adult male aorta and vein cDNA,
RIKEN full-length enriched library,
clone: A530041M22
3.5 1.7 3.3 5.5
MEK-dependent
Mm.282092 Hsp40 9.2 6.8 2.0 8.8
Mm.282092 Hsp40 6.1 4.3 1.6 6.1
Mm.248335 FosB 16.1 16.7 4.7 13.7
Mm.249333 RIKEN cDNA 1300002F13 gene 24.9 13.4 7.4 23.7
Mm.6215 Fra-1 18.0 14.1 5.6 15.8
Mm.249333 RIKEN cDNA 1300002F13 gene 36.5 20.9 14.4 38.9
Mm.4791 Epiregulin 13.5 11.0 5.4 16.6
Mm.289681 Diphtheria toxin receptor 12.4 7.3 5.1 15.7
Mm.6215 Fra-1 11.7 9.1 5.0 10.1
Mm.290421 Egr-2 13.3 9.8 5.7 11.3
Mm.28405 Serum/glucocorticoid-regulated kinase 8.1 4.9 3.8 7.7
PI3K-dependent
Mm.273188 Coagulation factor III 3.2 2.6 3.6 1.5
AV260654 AV260654 2.3 2.3 2.6 1.1
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expression of mcp-1, myc, adrenomedullin, ccr-4, tis 11b, and
mcp-3 genes were enhanced in response to PDGF treatment
and that in each case 2 M SU6656 inhibited the PDGF-in-
duced increase in gene expression (Fig. 3A). We then selected
three of these six genes and analyzed expression levels further
by using quantitative RPA. These data confirm that mRNA
expression levels of MCP-1, MCP-3, and adrenomedullin were
significantly increased in response to PDGF and were potently
inhibited by SU6656 (Fig. 3B). The apparent small PDGF-
induced increase in the expression of -actin is likely because of
the simultaneous use of four different riboprobes in this exper-
iment, and we generally do not see very significant increases in
-actin expression in response to PDGF treatment (see Fig.
5B). These data confirm the gene expression data shown in
Table I and validate the identity of a set of genes induced by
PDGF through SFK activity.
We identified a set of PDGF-inducible genes that signal
through SFKs. However, SFKs are known to also participate in
signaling through other pathways, notably the Ras-MAPK
pathways and the PI3K pathways (2). To determine which
genes were specifically dependent on SFK activity for increased
expression in response to PDGF, quiescent NIH3T3 cells were
treated with 25 ng/ml PDGF or vehicle for 1 h in the presence
of 2 M SU6656, 10 M U0126, 7.5 M LY294002, or vehicle. For
these analyses, gene expression was evaluated by using a
newer version of the Affymetrix GeneChip arrays (MOE 430A)
as described under “Experimental Procedures.” Expression
data were analyzed using the following filters: values were
present in all samples; sample intensity values were greater
than 50 units and differed by more than 100 intensity units
from reference; sample values genes were increased at least
2-fold in response to PDGF treatment, and genes were inhib-
ited at least 50% by one of the three inhibitors. This filtering
resulted in the inclusion of 174 probe IDs that were induced at
least 2-fold by PDGF, and of these 6 were only inhibited at least
50% by 2 M SU6656, 11 were only inhibited at least 50% by 10
M U0126, and 2 were only inhibited at least 50% by 7.5 M
LY294002 (Table II). All of the 23 probe IDs that passed the
above filtering criteria were subjected to unsupervised hierar-
chical clustering so that changes in gene expression across
samples could be readily observed. The cluster diagram of these
mean-centered data indicates relative high and low expression
for the given probe ID as shown in Fig. 4 by red and green boxes,
respectively. These data demonstrate that each inhibitor alone
has little effect on basal levels of gene expression and that
PDGF treatment induces the expression of a set of genes, which
are differentially affected by inhibitors.
We used semi-quantitative RT-PCR and RPA to validate
these gene expression data as described above. RT-PCRs were
performed in triplicate, and -actin was used as a control for
relative amounts of template cDNA. Expression levels of four
putative SFK-specific genes (mcp-1, fos, ccr-4, and ad-
renomedullin) were greatly reduced by SU6656 but only
slightly affected by U0126 or LY294002 (Fig. 5A). In contrast,
expression levels of four putative MEK-specific genes (hsp40,
fra-1, epiregulin, and egr-2) were greatly reduced by U0126 but
only slightly by SU6656 or LY294002 (Fig. 5A). These results
were further confirmed by using quantitative RPA analysis.
Specifically, mRNA levels of MCP-1 and adrenomedullin were
enhanced in response to PDGF treatment, but levels were
reduced by treatment with 2 M SU6656 (Fig. 5B). FosB and
Fra-1 mRNA levels were also increased by PDGF treatment,
but in this case expression was specifically inhibited by 10 M
U0126 (Fig. 5B).
Several of the PDGF-inducible genes that we had previously
identified as being selectively responsive to SU6656 when us-
FIG. 4. Hierarchical clustering of
gene expression data of PDGF-induc-
ible genes. Quiescent NIH3T3 cells were
treated for 1 h with 25 ng/ml PDGF or
vehicle in the presence of 2 M SU6656,
10 M U0126, 7.5 M LY294002, or vehi-
cle. Global patterns of gene expression
were identified by using Affymetrix
Mouse Expression 430A GeneChip ar-
rays, and gene expression ratios were
log2-transformed prior to analysis so that
relative increases and decreases in gene
expression are represented on a linear
scale. Expression data were filtered to in-
clude only those probe IDs whose expres-
sion was induced at least 2-fold in re-
sponse to PDGF, with respect to quiescent
NIH3T3 reference, and was reduced at
least 2-fold in response to inhibitor. These
data were subjected to mean-centered un-
supervised hierarchical clustering so that
relative changes in gene expression
across samples could be readily observed.
Red and green boxes indicate relative high
and low expression, respectively, for the
given probe ID. Probe IDs responsive to 2
M SU6656 are labeled in blue; probe IDs
responsive to 10 M U0126 are labeled in
red, and probe IDs responsive to 7.5 M
LY294002 are labeled in brown.
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ing the MG U74Av2 chip (Table I and Fig. 3) failed to pass the
stringent filtering criteria used when analyzing expression
data using the MOE 430A chip (data not shown). We therefore
directly tested the effects of the other kinase inhibitors on two
of the genes that we had previously identified, mcp-3 and tis
11b, using RT-PCR, as well as RPA in the case of MCP-3.
Expression levels of both genes were induced in response to
PDGF, inhibited significantly by SU6656, and only slightly
inhibited by U0126 or LY294002 (Fig. 5, A and B). In sum,
these results suggest that PDGF regulates immediate early
gene expression by signaling through a discrete SFK pathway,
which is at least somewhat distinct from the Ras-MAPK and
PI3K pathways.
MEK-dependent Genes—Our data demonstrate that PDGF-
induced expression of some genes was dependent on MEK
activity. To confirm that the small molecule inhibitors in our
model system are regulating gene expression through specific
inhibition of the intended signaling proteins, we compared the
effects of two different MEK1/2 inhibitors on PDGF-stimulated
gene expression. Quiescent NIH3T3 cells were treated with 25
ng/ml PDGF or vehicle for 1 h in the presence of 10 M U0126,
50 M PD98059, or vehicle. Global patterns of gene expression
were analyzed by using Affymetrix MG U74Av2 GeneChip
arrays. Expression data were analyzed by using the following
filters: values were present in all samples; sample intensity
values were greater than 50 units and differed by more than
100 intensity units from reference; and sample values were
increased at least 2-fold in response to PDGF, and increased no
more than 1.5-fold by one or by both of the inhibitors. This
filtering resulted in the inclusion of 189 probe IDs that were
induced at least 2-fold by PDGF, and of these 19 were induced
no more than 1.5-fold in the presence of 10 M U0126 or 50 M
PD98059, 11 were induced no more than 1.5-fold in the pres-
ence of 10 M U0126 alone, and 14 were induced no more than
1.5-fold in the presence of 50 M PD98059 alone (Table III).
Generally, the same genes were inhibited by both MEK1/2
inhibitors, even though in some cases the level of inhibition
failed to rise above the filtering criteria (data not shown).
However, there were notable exceptions. For example, the ex-
pression data suggested that Fra-1 was PDGF-inducible and
responsive to both U0126 and PD98059 but that Btg-2 was
PDGF-inducible and responsive to U0126 but not PD98059
(Table III).
RT-PCR was used to validate these gene expression data.
RT-PCRs were performed in duplicate, and -actin was used as
a control for relative amounts of template cDNA. PDGF-in-
duced expression levels of Fra-1 were potently inhibited by 10
M U0126 as well as by 50 M PD98059, but the PDGF-induced
expression of Btg-2 was inhibited only by 10 M U0126 (Fig.
6A). To confirm that both inhibitors were blocking MEK1/2
activity in our model system at the concentrations used, quies-
cent NIH3T3 cells were treated with increasing durations of 25
ng/ml PDGF as indicated in the presence of 10 M U0126, 50
M PD98059, or vehicle. MEK1/2 activity was assayed by im-
munoblotting for activated (tyrosine-phosphorylated) ERK1/2.
PDGF rapidly induced ERK2 phosphorylation (within 5 min),
and this phosphorylation was completely blocked by either 10
M U0126 or 50 M PD98059 (Fig. 6B). In addition, 2 M
SU6656 had no effect on PDGF-stimulated ERK1/2 phospho-
rylation (Fig. 6B). These results suggest that most PDGF-
induced and putative MEK1/2-specific genes are sensitive to
two different MEK1/2 inhibitors but with some notable excep-
tions. This might reflect the fact that the inhibitors we used are
not totally selective for MEK1/2 and also inhibit other kinases.
For example, 10 M U0126 also potently inhibits MEK5 (and
phosphorylation of its substrate, ERK5) in EGF- and hepato-
cyte growth factor-treated renal epithelial cells and HeLa cells
(14, 15). In contrast, PD98059 only effectively inhibits MEK5
activation in EGF-treated cells at concentrations higher than
those reported here (14, 15). Similarly, PD98059 may also bind
and inhibit specific target molecules. For example, PD98059
has been reported to inhibit cyclooxygenases I and II, even
though U0126 failed to inhibit these enzymes even at concen-
trations that completely block MAPK activation (16, 17).
PDGF Enhances the mRNA Stability, but Not the Transcrip-
tion, of SFK-specific Genes—myc, which was identified as a
PDGF-inducible and SFK-specific gene in the current screen
(Table I), has been an ongoing gene of interest in our laboratory
(4, 9, 10). It has been shown previously (18) that serum growth
factors regulate expression of the myc gene primarily at the
level of mRNA stability, rather than at the level of gene tran-
scription. To test whether PDGF also promotes myc mRNA
increases through stabilization, and whether other PDGF-in-
ducible and SFK-specific genes are similarly regulated, we
used nuclear run-off assays to measure the rates of transcrip-
tion for a subset of PDGF-inducible and SFK-specific genes. The
rate of transcription of themyc gene was detectable in quiescent
NIH3T3 cells, and it did not change in response to PDGF over a
period of 0–60 min (Fig. 7A). As a control, we collected the
material comprising the cytosolic fraction of the cell lysate from
these run-off assays (containing total RNA) and used RPA to
FIG. 5. RT-PCR and RPA analysis of SFK-dependent and MEK-
dependent genes. Quiescent NIH3T3 cells were treated for 1 h with
25 ng/ml PDGF or vehicle in the presence of 2 M SU6656, 10 M
U0126, 7.5 M LY294002, or vehicle. A, by using equivalent amounts of
cDNA for each reaction, gene-specific primer pairs were used to amplify
small segments of genes by PCR. Reactions were performed in tripli-
cate, and -actin was used as a control for relative amounts of template
cDNA. B, ribonuclease protection assays were performed using gene-
specific probes. Reactions were performed in duplicate, and -actin was
used as a control for relative amounts of total RNA. The data presented
are derived from two separate assays, each of which had internal
positive and negative controls.
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confirm that myc mRNA was indeed increased in response to
PDGF treatment (Fig. 7B). These data confirm the stabilization
ofmycmRNA in response to growth factors and further suggest
SFKs may be involved in regulating mRNA stability.
Providing further evidence for this mechanism, transcription
of both mcp-1 and mcp-3 genes was also high in quiescent
NIH3T3 cells and was unaffected by PDGF treatment (Fig. 7A),
even though we demonstrated that these genes were induced in
TABLE III
The expression of a subset of PDGF-inducible genes is responsive to the MEK inhibitors U0126 and PD98059
Quiescent NIH3T3 cells were treated for 1 h with 25 ng/ml PDGF or vehicle in the presence of 10 M U0126, 50 M PD98059, or vehicle. Global
patterns of gene expression were identified using Affymetrix MOE 430A GeneChip arrays (for details see Table I). Gene expression data were
analyzed using the following filters: values were greater than 50 units; values differed by more than 50 intensity units from reference; values were
increased at least 2-fold in response to PDGF, and values were increased no more than 1.5-fold by PDGF in the presence of inhibitor. This filtering
resulted in the inclusion of 150 probe IDs that were induced at least 2-fold by PDGF, and of these 11 were induced less than 1.5-fold by PDGF in
the presence of 10 M U0126, 14 were induced less than 1.5-fold by PDGF in the presence of 50 M PD98059, and 19 were induced less than 1.5-fold
by PDGF in the presence of either 10 M U0126 or 50 M PD98059. The list of these probe IDs is shown.
Unigene Gene encodes
Log2 gene expression ratio relative to quiescent fibroblasts
PDGF PDGF  U0126 PDGF  PD98059
U0126- and PD98059-responsive
Mm.1359 Urokinase plasminogen activator
receptor
3.6 2.4 1.9
Mm.248335 FosB 8.2 2.0 4.4
Mm.24096 Thrombomodulin 3.4 2.2 1.7
Mm.279106 Cofactor required for Sp1
transcriptional activation, subunit
8
2.0 1.3 1.2
Mm.3117 Pleckstrin homology-like domain,
family A, member 1
20.1 9.2 6.0
AV381829 AV381829 3.6 1.7 2.3
Mm.289681 Diphtheria toxin receptor 3.9 1.8 1.4
Mm.4863 Ubiquitin-conjugating enzyme E2
variant 1
2.4 1.4 1.6
Mm.1791 Dual specificity phosphatase 6 31.9 9.2 9.8
Mm.249333 RIKEN cDNA 1300002F13 gene 35.1 7.9 20.0
Mm.249333 RIKEN cDNA 1300002F13 gene 24.2 7.5 11.1
Mm.246398 TCDD-inducible poly(ADP-ribose)
polymerase
13.4 6.3 6.9
Mm.330818 Semaphorin 4B precursor 3.3 1.3 0.6
Mm.295252 Peptidylprolyl isomerase D
(cyclophilin D)
2.3 1.2 1.3
AW046181 AW046181 4.1 2.1 2.3
Mm.289824 Interleukin 1 receptor-like 1 6.4 1.9 2.2
Mm.289824 Interleukin 1 receptor-like 1 4.6 1.9 1.3
Mm.89888 Glutamate-cysteine ligase, catalytic
subunit
2.5 1.3 1.3
AF017128 Fra-1 10.7 5.0 5.1
U0126-responsive
U70475 Nuclear factor, erythroid derived 2,
like 2
2.4 1.4 1.8
Mm.101034 TG-interacting factor 5.0 2.9 4.0
Mm.1167 JunB oncogene 20.3 12.1 15.0
Mm.300399 SOCS-5 mRNA, complete cds 2.3 1.4 2.7
Mm.227 Integrin V 3.3 2.1 3.8
Mm.86541 CCR-4 13.4 8.5 12.7
Mm.239605 Btg-2 9.6 6.2 8.9
Mm.2093 Snail homolog 1 (Drosophila) 2.2 1.4 1.6
Mm.227506 DNA segment, Chr 7, ERATO Doi
458, expressed
10.6 6.8 11.9
Mm.290421 Egr-2 20.8 13.6 14.9
Mm.4499 Calcium channel, voltage-dependent,
L-type, 1C subunit
2.4 1.6 1.9
PD98059-responsive
Mm.25613 Immediate early response 3 16.6 16.4 7.1
Mm.272602 CCAAT/enhancer-binding protein (C/
EBP), 
5.0 3.7 2.3
Mm.292547 Prostaglandin-endoperoxide synthase
2
16.7 16.5 8.3
Mm.6522 Chemokine orphan receptor 1 2.2 1.6 1.1
Mm.239041 Dual specificity phosphatase 1 2.3 2.5 1.2
V00727 Fos 18.6 17.0 10.0
AF004100 Solute carrier family 30 (zinc
transporter), member 4
2.1 1.5 1.2
Mm.8042 Inhibin -A 4.1 3.3 2.4
L00039 Myc 7.6 5.3 4.4
Mm.4660 Chemokine (CXC motif) ligand 5 2.1 1.7 1.2
Mm.164948 Ecotropic viral integration site 2B 2.2 2.0 1.3
Mm.1068 B-cell leukemia/lymphoma 3 2.1 1.6 1.3
AV374868 Similar to suppressor of cytokine
signaling-3
5.6 4.7 3.5
D16497 Natriuretic peptide precursor type B 3.7 3.0 2.3
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response to PDGF specifically through SFKs (Table II and Figs.
3 and 5). The transcription of adrenomedullin, another PDGF-
inducible and SFK-specific gene, was also only slightly respon-
sive to PDGF (Fig. 7A). Finally, as a control for the run-off
assay, we determined rates of fos transcription in response to
PDGF. Previous data have shown that it is primarily fos tran-
scription that is induced in response to growth factor stimula-
tion (18), and we confirmed that fos transcription was highly
induced by PDGF treatment in our model system (Fig. 7A). In
sum, these data suggest that in response to growth factor the
role of SFKs is to signal stabilization of target mRNAs.
DISCUSSION
Our laboratory has recently focused on one particular output
of SFK activity, the growth factor-stimulated production of
Myc, a transcription factor required for efficient cell cycle tran-
sit. Previous work demonstrated that the block to PDGF-stim-
ulated DNA synthesis caused by dominant negative SFKs
could be overcome by expression of Myc (10). Another tran-
scription factor, Fos, was unable to rescue this block. Further-
more, Myc could not overcome the block caused by dominant
negative Ras. Together, these data suggested that SFKs ini-
tiate a signal transduction pathway, distinct from the classical
Ras-MAPK pathway, which culminates in Myc production. The
subsequent characterization and use of SU6656, an SFK inhib-
itor, confirmed that myc mRNA was in large part under SFK
control (9).
In fibroblasts, early reports suggested that PDGF increased
levels ofmycmRNA by increasing the rate ofmyc transcription
(19, 20). However, others have shown that the basal transcrip-
tion rate of myc in quiescent fibroblasts is high, and it is
unchanged by stimulation with serum or thrombin (21–24).
This suggests that it is primarily the stability of myc mRNA
that is affected by mitogens. Our data confirm that it is this
mRNA stability mechanism that operates in NIH3T3 cells in
response to PDGF stimulation. Our data also identify other
short lived SFK-specific RNAs (MCP-1, MCP-3, and ad-
renomedullin) that are regulated primarily by enhanced
mRNA stability. In the case of MCP-1, PDGF has been reported
to increase mcp-1 mRNA stability/levels in vascular smooth
muscle cells (25), although increases in mcp-1 transcription in
response to PDGF have also been detected in these cells (26).
There are also data to suggest that MCP-3 and adrenomedullin
expression are also regulated by mRNA stabilization, but what
roles PDGF or SFKs might play in those processes is unclear
(27, 28).
The control of the stability of short lived mRNAs is under
intense scrutiny, but how mitogenic signals impact this control
is not yet fully understood. Previous work has demonstrated
how the half-life ofmycmRNA is regulated. Two regions, one in
the 3-untranslated region (UTR) and one in the coding region
(CR), are involved (29, 30). The CR instability determinant
(CRD) in the myc CR targets myc mRNA for endonuclease
attack during translational pausing (31). A CRD-binding pro-
tein has been identified, which shields this region. CRD-bind-
ing protein is a member of the family of KH domain-containing
RNA-binding proteins (32, 33). It is highly expressed in fetal
tissues and in some cancer cell lines, and its expression may in
part explain high levels of Myc protein in these cases (34).
However, CRD-binding protein has not been detected in normal
adult cells, including fibroblasts. The 3-UTR of the myc gene
contains AU-rich elements (AUREs) that are frequently found
in unstable mRNAs (35). Several AURE-binding proteins have
been described. Some (such as HuR) stabilize and some (such
as AUF1 and tristetraprolin) destabilize transcripts (30). How-
ever, little is known regarding the influence of signaling path-
ways onmyc AURE-binding proteins. Most interestingly, one of
the SFK-specific PDGF-inducible genes we identified, Tis 11b,
is related to tristetraprolin and has recently been shown to
destabilize vascular endothelial growth factor mRNA in re-
FIG. 6. RT-PCR and Western blot
analysis validates genes likely to be
PDGF-inducible and responsive to
MEK inhibitors U0126 and PD98059.
A, quiescent NIH3T3 cells were treated
for 1 h with 25 ng/ml PDGF or vehicle in
the presence of 10 M U0126, 50 M
PD98059, or vehicle. By using equivalent
amounts of cDNA for each reaction, gene-
specific primer pairs were used to amplify
small segments of genes by PCR. Reac-
tions were performed in duplicate, and
-actin was used as a control for relative
amounts of template cDNA. B, quiescent
NIH3T3 cells were stimulated for 0–60
min with 25 ng/ml PDGF in the presence
or absence of 2 M SU6656, 10 M U0126,
50 M PD98059, or vehicle as indicated.
Levels of phospho-ERK1/2 and total
ERK1/2 protein were measured using
SDS-PAGE and immunoblotting.
FIG. 7. RPA and nuclear run-off analyses of SFK-specific
genes. Quiescent NIH3T3 cells were treated with 25 ng/ml PDGF for
increasing amounts of time as indicated. A, nuclei were isolated and
levels of mcp-1, mcp-3, myc, adrenomedullin, fos, and -actin gene
transcription were analyzed using nuclear run-off assays. Data are
taken from three separate run-off assays, each of which had internal
positive and negative controls. B, cytoplasmic fractions of cell lysates
were obtained, total RNA was isolated for each time point, and levels of
myc and -actin mRNAs were determined by RPA.
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sponse to adrenocorticotropic hormone (36). Thus, it is possible
that Tis 11b might also play a role in SFK-mediated mRNA
stability ofmyc or of other SFK-dependent genes. Furthermore,
the instability determinant need not be restricted to the 3-
UTR. mcp-1 mRNA, for example, contains a region within its
5-UTR that appears to destabilize the mRNA in response to
PDGF plus dexamethasone (37).
A recent report suggested that PDGF signals immediate
early gene expression with little or no specificity with regard to
signaling pathways. In this study, NIH3T3 cells were trans-
fected with wild-type PDGF-R or with a number of receptor
mutants that contained amino acid substitutions at sites that
mediate interaction with various signaling effectors, including
the Ras/MAPK and PI3K pathways. These investigators found
that, in response to PDGF-R activation, wild-type and mutant
receptors promoted the expression of an identical set of 64
immediate early genes in fibroblasts (11). However, our data
demonstrate that PDGF stimulation of SFK and MEK path-
ways each caused the increased expression of a specific set of
immediate early genes. In particular, we isolated a set of genes
that were induced by PDGF through SFK activity but not
MEK1/2 or PI3K. Furthermore, a recent report (38) described
the PDGF-stimulated increase in expression of specific sets of
genes in fibroblasts, including genes required for fatty acid and
cholesterol biosynthesis, in a PI3K-dependent manner. Finally,
a recent report (39) identified specific sets of genes that were
induced in response to PDGF through either MEK or PI3K
activity. What is the reason for the apparent discrepancy in
these observations? The differences most likely arise from the
differing methodologies employed. Fambrough et al. (11) mu-
tated known PDGF-R effector-binding sites and then measured
the effect that each mutant had on signaling gene expression in
response to receptor activation. Although this approach can
unambiguously determine whether stable association of signal-
ing intermediates with the PDGF-R is required, it does not
preclude the possibility that these proteins participate in
PDGF signaling without association. We used pharmacological
inhibitors of SFKs and other kinases, thus ensuring that all
enzyme activity was blocked. It is also possible that receptor
number and/or the concentration of PDGF used in these studies
has a significant impact on the gene expression profiles de-
tected. In our studies, we used 25 ng/ml PDGF (a submaximal
but physiological dose) and unengineered cells, whereas Fam-
brough et al. (11) used cells engineered to express receptor
mutants and saturating levels of growth factor.
Our data are in agreement with several other reports iden-
tifying serum- and PDGF-inducible genes (38–41). In particu-
lar, many of the PDGF-inducible genes we identified (e.g. junB,
tis 11b, fra-1, mcp-1, myc, etc.) were also described in a recent
report (38) analyzing gene expression in fibroblasts induced by
1–24 h of PDGF treatment. Many of the PI3K-dependent genes
these investigators identified were induced only after 24 h of
growth factor stimulation. Because we measured gene expres-
sion after just 1 h of PDGF treatment, this might explain how
we failed to detect PDGF-inducible, PI3K-dependent genes.
A recent report (42) used Affymetrix GeneChip analysis to
identify a set of genes that are induced in Src-transformed
cells. Many of the Src-transformed genes identified were also
up-regulated in colon tumors. Generally, only a few of the genes
we identified are represented in this “Src transformation fin-
gerprint” (data not shown). We have also analyzed gene expres-
sion patterns in fibroblasts transformed with an activated form
of Src (SrcY527F), and we compared this pattern of expression
with PDGF-inducible genes generally and SFK-dependent
genes specifically. We also detected very little overlap in the
patterns of gene expression. Only a few of the PDGF-inducible
and SFK-dependent genes we identified in the current study
were overexpressed in Src-transformed fibroblasts, and the
pattern of gene expression in Src-transformed cells was very
different from PDGF-induced gene expression.2 These data
suggest that transformation drives a different set of genes than
growth factor stimulation. This is possibly because many genes
may be induced secondarily in response to Src transformation
and not primarily because of SFK activity per se.
In summary, microarray analysis has revealed a distinct set
of mRNAs whose increased expression in response to PDGF is
dependent upon SFKs. Most interestingly, many of these genes
are regulated at the level of mRNA stabilization. One of these
genes is myc, whose product is a transcription factor required
for mitogenesis. We have preliminary evidence3 that PDGF
stimulation of quiescent fibroblasts causes an SFK-dependent
change in the composition of proteins binding to the AURE in
the 3-UTR of the myc gene. It will be important in the future
to determine how SFKs regulate AURE-binding proteins.
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